- Home
- COLL vs PARR Comparison
COLL vs PARR Comparison
Compare COLL & PARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- PARR
- Stock Information
- Founded
- COLL 2002
- PARR 1984
- Country
- COLL United States
- PARR United States
- Employees
- COLL N/A
- PARR N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- PARR Integrated oil Companies
- Sector
- COLL Health Care
- PARR Energy
- Exchange
- COLL Nasdaq
- PARR Nasdaq
- Market Cap
- COLL 1.1B
- PARR 903.1M
- IPO Year
- COLL 2015
- PARR N/A
- Fundamental
- Price
- COLL $29.58
- PARR $17.64
- Analyst Decision
- COLL Strong Buy
- PARR Buy
- Analyst Count
- COLL 6
- PARR 6
- Target Price
- COLL $42.00
- PARR $28.00
- AVG Volume (30 Days)
- COLL 440.1K
- PARR 1.0M
- Earning Date
- COLL 11-07-2024
- PARR 11-04-2024
- Dividend Yield
- COLL N/A
- PARR N/A
- EPS Growth
- COLL 757.11
- PARR N/A
- EPS
- COLL 2.16
- PARR 5.32
- Revenue
- COLL $599,245,000.00
- PARR $8,325,746,999.00
- Revenue This Year
- COLL $13.02
- PARR N/A
- Revenue Next Year
- COLL $18.01
- PARR N/A
- P/E Ratio
- COLL $13.68
- PARR $3.32
- Revenue Growth
- COLL 9.62
- PARR 5.96
- 52 Week Low
- COLL $25.07
- PARR $14.84
- 52 Week High
- COLL $42.29
- PARR $40.70
- Technical
- Relative Strength Index (RSI)
- COLL 26.96
- PARR 55.44
- Support Level
- COLL $29.69
- PARR $16.46
- Resistance Level
- COLL $35.62
- PARR $17.69
- Average True Range (ATR)
- COLL 1.41
- PARR 0.89
- MACD
- COLL -0.39
- PARR 0.29
- Stochastic Oscillator
- COLL 6.36
- PARR 88.19
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.